受体酪氨酸激酶RET抑制剂(BBT594) | 882405-89-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 受体酪氨酸激酶RET抑制剂(BBT594)
• 英文名称: 5-((6-ethanoylaminopyrimidin-4-yl)oxy)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)dihydroindole-1-carboxamide
• 英文别名: 5-((6-ethanoylaminopyrimidin-4-yl)oxy)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)indoline-1-carboxamide；5-((6-ethanamidopyrimidin-4-yl)oxy)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)indoline-1-carboxamide；5-((6-acetamidopyrimidin-4-yl)oxy)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)indoline-1-carboxamide；Nvp-bbt594；5-(6-acetamidopyrimidin-4-yl)oxy-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-2,3-dihydroindole-1-carboxamide
• CAS: 882405-89-2
• 化学式: C₂₈H₃₀F₃N₇O₃
• 分子量: 569.587
• InChiKey: VQLNKQZLPGLOSI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  41
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  103
• 氢给体数：
  2
• 氢受体数：
  10

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

文献信息

• [EN] COMPOUNDS AND METHODS OF TREATING CANCERS<br/>[FR] COMPOSÉS ET MÉTHODES DE TRAITEMENT DE CANCERS
  申请人：CULLGEN SHANGHAI INC

  公开号：WO2020200291A1

  公开（公告）日：2020-10-08

  This disclosure relates to heterobifunctional compounds (e.g., bi-functional small molecule compounds), compositions comprising one or more of the heterobifunctional compounds, and to methods of use the heterobifunctional compounds for the treatment of certain disease in a subject in need thereof. The disclosure also relates to methods for identifying such heterobifunctional compounds.

  这份披露涉及异双功能化合物（例如，双功能小分子化合物），包括一种或多种异双功能化合物的组合物，以及使用这些异双功能化合物治疗患有特定疾病的需要该类治疗的受试者的方法。该披露还涉及识别此类异双功能化合物的方法。
• Cyclic Diaryl Ureas Suitable as Tyrosine Kinase Inhibitors
  申请人：Bold Guido

  公开号：US20080039440A1

  公开（公告）日：2008-02-14

  The invention relates to novel compounds of Formula I: wherein p is 1, 2 or 3; n is 0, 1, 2 or 3; m is 0, 1, 2 or 3; A is CR c , S, NR c or O, where R c is H or lower alkyl; X, Y and Z are each independently selected from N or C—R 3 , wherein at least two of X, Y and Z are N; and each R a is independently selected from hydrogen and lower-alkyl; each R b is hydrogen or lower-alkyl; G is a group Ar or represents CN or unsubstituted or substituted lower alkyl; Ar is a saturated or unsaturated cyclic group, which is substituted or unsubstituted and maybe a five or six membered monocyclic or a 8, 9, 10, 11 or 12 membered bicyclic or tricyclic ring and may contain 0, 1, 2 or 3 heteroatoms selected from O, N and S; and wherein the radicals have R 1 , R 2 , R 3 and R 4 have the meanings as defined herein, to salts, esters, N-oxides or prodrugs thereof; and their use in the treatment of protein kinase dependent diseases, their use in the manufacture of pharmaceutical compositions for use in the treatment of said diseases, methods of use of diary urea derivatives in the treatment of said diseases, pharmaceutical preparations comprising these novel diaryl urea derivatives, processes for the manufacture of the novel diaryl urea derivatives, the use or methods of use of the novel diaryl urea derivatives as mentioned above, and/or these novel diaryl urea derivatives for use in the treatment of the animal or human body.

  本发明涉及公式I的新化合物：其中p为1、2或3；n为0、1、2或3；m为0、1、2或3；A为CRc、S、NRcor O，其中Rcis H或较低的烷基；X、Y和Z各自独立地选择自N或C—R3，其中至少有两个X、Y和Z为N；而每个Rais独立选择自氢和较低的烷基；每个Rbis氢或较低的烷基；G是Ar基团或表示CN或未取代或取代的较低烷基；Ar是饱和或不饱和的环状基团，其被取代或未取代，并且可能是五元或六元的单环或8、9、10、11或12元的双环或三环，并且可能包含0、1、2或3个从O、N和S中选择的杂原子；其中基团具有R1、R2、R3和R4的含义如本文所定义，其盐、酯、N-氧化物或前药；并且它们在蛋白激酶依赖性疾病的治疗中的使用，它们在制造用于治疗该等疾病的药物组合物中的使用，二苯基脲衍生物在治疗该等疾病中的使用方法，包括这些新的二苯基脲衍生物的制药制剂，制造新的二苯基脲衍生物的方法，上述提到的新的二苯基脲衍生物的使用或使用方法，以及/或这些新的二苯基脲衍生物用于治疗动物或人体。
• FUSED HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS
  申请人：Array Biopharma, Inc.

  公开号：EP3849986A1

  公开（公告）日：2021-07-21
• 7-((3,5-DIMETHOXYPHENYL)AMINO)QUINOXALINE DERIVATIVES AS FGFR INHIBITORS FOR TREATING CANCER
  申请人：Array Biopharma, Inc.

  公开号：EP3898615A1

  公开（公告）日：2021-10-27
• SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS INHIBITORS OF FGFR TYROSINE KINASES
  申请人：Array Biopharma, Inc.

  公开号：EP3898626A1

  公开（公告）日：2021-10-27